The purpose of this study is to evaluate the efficacy and safety of an investigational medicine in people living with Idiopathic Pulmonary Fibrosis (IPF).
#IdiopathicPulmonaryFibrosis (#IPF) is a serious and progressive disease with symptoms including shortness of breath, a persistent dry cough, and unexplained weight loss.
Learn more about this rare condition here: https://t.co/GxgkgljQrj
Want to learn more about potential participation in the WISPer Trial for Idiopathic Pulmonary Fibrosis (IPF)? Find eligibility criteria, trial details, and more: https://t.co/jxOnLvoMSh #IPF#ClinicalTrial#IdiopathicPulmonaryFibrosis
If you meet eligibility criteria and would like to learn more about participation in the WISPer Trial for #IPF, use our trial site locator map to find a clinical trial site near you. https://t.co/YuuQSmzEqb
#IPF#ClinicalTrial#IdiopathicPulmonaryFibrosis
Matt, who lives with IPF, shares his reaction to his diagnosis. If you live with IPF, did you have a similar response to your diagnosis?
This #RareDiseaseMonth, we encourage you to generate IPF awareness. Find helpful disease info here: https://t.co/GxgkglkogR
Feb. is #RareDiseaseMonth – a time to recognize rare conditions like #IPF and the approx. 30 million Americans who live with rare diseases.
If you live with IPF, we encourage you to share disease resources this month. Find helpful info here: https://t.co/KGD5VbktvO
Do you live with #IdiopathicPulmonaryFibrosis (IPF)? You may be eligible to participate in the WISPer Trial; a study to evaluate the efficacy and safety of an investigational medicine in people living with IPF.
Learn more: https://t.co/jxOnLvoMSh
#IPF#clinicaltrial
Want to find a WISPer clinical trial site near you?
If you meet the eligibility criteria and would like to learn more about participation in the WISPer study for IPF, check out our trial sites locator tool to find a clinical trial site near you. https://t.co/YuuQSmzEqb
Interested in learning about Idiopathic Pulmonary Fibrosis (IPF) clinical trial participation in the New Year? Find information about the WISPer Trial here: https://t.co/jxOnLvoMSh
#IPF#ClinicalTrial#IdiopathicPulmonaryFibrosis
WISPer Trial:
-Approximately 164 participants expected to enroll
-Study is up to 32 weeks, including a 4-week screening period, 24-week treatment period and 4-week safety follow-up period
-Participants are randomized in a 1:1 ratio to receive investigational medication or placebo
Do you live with #IPF?
You may be eligible to participate in the WISPer Trial if:
- You are age 40 years or older
- Have been diagnosed with IPF within the past 7 years
- Have a Forced Vital Capacity (FVC) of 45% predicted or greater
Learn more: https://t.co/jxOnLvoMSh
If you have received a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within the past 7 years and are 40 years or older, you may be eligible to participate in the WISPer Trial.
Learn more: https://t.co/GVcTxJi0dE
#IPF#idiopathicfibrosis#clinicaltrials
Want to learn about potential participation in the WISPer Trial for Idiopathic Pulmonary Fibrosis (IPF)?
Discover eligibility criteria, trial details, and more: https://t.co/jxOnLvoMSh
#IPF#ClinicalTrial#IdiopathicPulmonaryFibrosis
Individuals living with IPF may be able to participate in the WISPer Trial.
Find eligibly criteria and learn more about the trial here: https://t.co/s87RLO4fLZ
#IPF#ClinicalTrial#IdiopathicPulmonaryFibrosis
As the holidays approach, you may be looking for a way to discuss your IPF diagnosis with friends and family.
If you need help explaining your condition, we encourage to use this video as a tool:
https://t.co/NeNzcKTvN6
#IPF#ClinicalTrial#IdiopathicPulmonaryFibrosis